<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="682">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04497272</url>
  </required_header>
  <id_info>
    <org_study_id>20-PP-18</org_study_id>
    <nct_id>NCT04497272</nct_id>
  </id_info>
  <brief_title>Assesment of the Metabolomic Signature in COVID-19 Patients</brief_title>
  <acronym>SignCov</acronym>
  <official_title>Assesment of the Metabolomic Signature in COVID-19 Patients (SignCov Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolomics is the analysis of small molecules in a biological sample (cells, tissues or
      biological fluids). It can potentially detect very sensitively any change related to a
      pathology or exposure to a toxic agent. The analyses are fast, inexpensive and therefore
      applicable in routine, particularly in health care. Given the emergence of this new disease,
      COVID-19, there is a real need to better understand the pathophysiological mechanisms of
      SARS-CoV-2 infection. In this context, metabolomics could have a place and could lead to the
      development of interesting diagnostic or prognostic tools. The objective of this study is to
      identify, through the analysis of biological samples (blood and urine), whether there is a
      metabolomic signature in patients with COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 7, 2020</start_date>
  <completion_date type="Anticipated">October 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patient with COVID-19 disease</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identifying the metabolomic signature</measure>
    <time_frame>4 weeks after the inclusion</time_frame>
    <description>Identify a metabolomic profile using liquid chromatography combined with mass spectrometry (LC-MS) on the serum and urine of COVID-19 patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of the metabolomic profile according to clinical severity.</measure>
    <time_frame>4 weeks after the inclusion</time_frame>
    <description>Identification of the metabolomic profile of patients infected with SARS CoV 2 in the following subgroups: pauci-symptomatic patients, symptomatic patients without clinical severity criteria, and critically ill COVID-19 patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>The metabolomic signature of COVID-19 patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>COVID-19 patients</intervention_name>
    <description>It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.</description>
    <arm_group_label>The metabolomic signature of COVID-19 patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient over 18 years of age

          -  affiliated to a social security scheme

          -  consultant in the emergency department and/or being hospitalized for suspected SARS
             CoV infection

          -  confirmation, after medical examination, of the need for a biological examination
             (this will negate the need for additional venipuncture)

        Exclusion criteria:

          -  Patient who do not meet inclusion criteria

          -  Person subject to a guardianship order

          -  Opposition to the use of the data or samples (withdrawal of non-opposition) /
             Sponsor's or investigator's decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>OCCELLI Céline</last_name>
    <role>Principal Investigator</role>
    <affiliation>Néphrologie, CHU de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>OCCELLI Céline</last_name>
    <phone>+33492033204</phone>
    <email>occelli.c@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de nice</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>OCCELLI Céline</last_name>
      <phone>+33492033204</phone>
      <email>occelli.c@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>OCELLI Celine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

